PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin(Cornell University), Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center)
Cited by 148
Related Papers
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
|Nature Communications|2016|960
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
|Clinical Cancer Research|2016|583
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
|Nature Communications|2020|456